Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Research Perspective on Utilizing and Valuing Tumor Biobanks.

Rush A, Matzke L, Cooper S, Gedye C, Byrne JA, Watson PH.

Biopreserv Biobank. 2018 Dec 21. doi: 10.1089/bio.2018.0099. [Epub ahead of print]

PMID:
30575428
2.

Factors that drive the increasing use of FFPE tissue in basic and translational cancer research.

Gaffney EF, Riegman PH, Grizzle WE, Watson PH.

Biotech Histochem. 2018;93(5):373-386. doi: 10.1080/10520295.2018.1446101. Epub 2018 Aug 16. Review.

PMID:
30113239
3.

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.

Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.

BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.

4.

Malignant Epithelial Transformation in Phyllodes Tumor: A Population-Based Case Series.

Widya RL, Rodrigues MF, Truong PT, Watson PH, Weir LM, Knowling MA, Wai ES.

Cureus. 2017 Nov 3;9(11):e1815. doi: 10.7759/cureus.1815.

5.

Radiation generates an abscopal response and complete resolution of metastatic squamous cell carcinoma of the anal canal: a case report.

Joe MB, Lum JJ, Watson PH, Tonseth RP, McGhie JP, Truong PT.

J Gastrointest Oncol. 2017 Dec;8(6):E84-E89. doi: 10.21037/jgo.2017.06.15.

6.

An Australian Biobank Certification Scheme: A Study of Economic Costs to Participating Biobanks.

Ling R, Rush A, Carter C, Carpenter J, Watson PH, Byrne JA, Searles A.

Biopreserv Biobank. 2018 Feb;16(1):53-58. doi: 10.1089/bio.2017.0095. Epub 2017 Dec 7.

PMID:
29215912
7.

PD-L1 and intratumoral immune response in breast cancer.

Wang ZQ, Milne K, Derocher H, Webb JR, Nelson BH, Watson PH.

Oncotarget. 2017 May 30;8(31):51641-51651. doi: 10.18632/oncotarget.18305. eCollection 2017 Aug 1.

8.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

9.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

10.

Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis.

Yang Y, Yang HH, Hu Y, Watson PH, Liu H, Geiger TR, Anver MR, Haines DC, Martin P, Green JE, Lee MP, Hunter KW, Wakefield LM.

Oncotarget. 2017 May 9;8(19):30621-30643. doi: 10.18632/oncotarget.15695.

11.

Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer.

Feng X, Li H, Kornaga EN, Dean M, Lees-Miller SP, Riabowol K, Magliocco AM, Morris D, Watson PH, Enwere EK, Bebb G, Paterson A.

Oncotarget. 2016 Dec 27;7(52):85798-85812. doi: 10.18632/oncotarget.12622.

12.
13.

Biospecimen User Fees: Global Feedback on a Calculator Tool.

Matzke LA, Babinszky S, Slotty A, Meredith A, Castillo-Pelayo T, Henderson MK, Simeon-Dubach D, Schacter B, Watson PH.

Biopreserv Biobank. 2017 Feb;15(1):57-64. doi: 10.1089/bio.2016.0027. Epub 2016 Aug 30.

14.

Biospecimen Complexity-the Next Challenge for Cancer Research Biobanks?

Watson PH.

Clin Cancer Res. 2017 Feb 15;23(4):894-898. doi: 10.1158/1078-0432.CCR-16-1406. Epub 2016 Aug 22.

15.

CD103 and Intratumoral Immune Response in Breast Cancer.

Wang ZQ, Milne K, Derocher H, Webb JR, Nelson BH, Watson PH.

Clin Cancer Res. 2016 Dec 15;22(24):6290-6297. Epub 2016 Jun 7.

16.

CD74 and intratumoral immune response in breast cancer.

Wang ZQ, Milne K, Webb JR, Watson PH.

Oncotarget. 2017 Feb 21;8(8):12664-12674. doi: 10.18632/oncotarget.8610.

17.

Fundamental Considerations for Biobank Legacy Planning.

Matzke LA, Fombonne B, Watson PH, Moore HM.

Biopreserv Biobank. 2016 Apr;14(2):99-106. doi: 10.1089/bio.2015.0073. Epub 2016 Feb 18.

18.

A Model to Estimate Frozen Tissue Collection Targets in Biobanks to Support Cancer Research.

Meredith AJ, Slotty A, Matzke L, Babinszky S, Watson PH.

Biopreserv Biobank. 2015 Oct;13(5):356-62. doi: 10.1089/bio.2014.0081. Epub 2015 Sep 29.

PMID:
26418967
19.

The importance of biobanking in cancer research.

Castillo-Pelayo T, Babinszky S, LeBlanc J, Watson PH.

Biopreserv Biobank. 2015 Jun;13(3):172-7. doi: 10.1089/bio.2014.0061.

PMID:
26035006
20.

Intratumoural inflammation and endocrine resistance in breast cancer.

Murray JI, West NR, Murphy LC, Watson PH.

Endocr Relat Cancer. 2015 Feb;22(1):R51-67. doi: 10.1530/ERC-14-0096. Epub 2014 Nov 17. Review.

PMID:
25404688
21.

Funding sources for Canadian biorepositories: the role of user fees and strategies to help fill the gap.

Barnes RO, Schacter B, Kodeeswaran S; CTRNet Management Committee, Watson PH.

Biopreserv Biobank. 2014 Oct;12(5):300-5. doi: 10.1089/bio.2014.0052. Epub 2014 Oct 14.

PMID:
25314324
22.

A practical tool for modeling biospecimen user fees.

Matzke L, Dee S, Bartlett J, Damaraju S, Graham K, Johnston R, Mes-Masson AM, Murphy L, Shepherd L, Schacter B, Watson PH.

Biopreserv Biobank. 2014 Aug;12(4):234-9. doi: 10.1089/bio.2014.0008.

PMID:
25162459
23.

Biobank classification: communicating biorepository diversity.

Watson PH.

Biopreserv Biobank. 2014 Jun;12(3):163-4. doi: 10.1089/bio.2014.1231. No abstract available.

PMID:
24955732
24.

Individual investigator profiles of biospecimen use in cancer research.

Braun L, Lesperance M, Mes-Massons AM, Tsao MS, Watson PH.

Biopreserv Biobank. 2014 Jun;12(3):192-8. doi: 10.1089/bio.2013.0092. Epub 2014 Jun 11.

PMID:
24918606
25.

Impact of a Permission to Contact (PTC) platform on biobank enrollment and efficiency.

LeBlanc J, Dee S, Braun L, Daudt H, Cheah S, Watson PH.

Biopreserv Biobank. 2013 Jun;11(3):144-8. doi: 10.1089/bio.2013.0004. Epub 2013 May 31.

PMID:
24850090
26.

Permission to contact (PTC)--a strategy to enhance patient engagement in translational research.

Cheah S, O'Donoghue S, Daudt H, Dee S, LeBlanc J, Braun L, Barnes R, Vercauteren S, Boone RH, Watson PH.

Biopreserv Biobank. 2013 Aug;11(4):245-52. doi: 10.1089/bio.2013.0023.

PMID:
24845592
27.

Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.

Le Page C, Köbel M, de Ladurantaye M, Rahimi K, Madore J, Babinszky S, Bachvarov DR, Bachvarova M, Beauchamp MC, Cass CE, Chadwick D, Colleen C, Damaraju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piché A, Shaw P, Roehrl MH, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM.

Biopreserv Biobank. 2013 Apr;11(2):83-93. doi: 10.1089/bio.2012.0044. Erratum in: Biopreserv Biobank. 2013 Aug;11(4):257. Roehrl, Michael H A [added].

PMID:
24845429
28.

A framework for biobank sustainability.

Watson PH, Nussbeck SY, Carter C, O'Donoghue S, Cheah S, Matzke LA, Barnes RO, Bartlett J, Carpenter J, Grizzle WE, Johnston RN, Mes-Masson AM, Murphy L, Sexton K, Shepherd L, Simeon-Dubach D, Zeps N, Schacter B.

Biopreserv Biobank. 2014 Feb;12(1):60-8. doi: 10.1089/bio.2013.0064.

29.

Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.

Townsend KN, Spowart JE, Huwait H, Eshragh S, West NR, Elrick MA, Kalloger SE, Anglesio M, Watson PH, Huntsman DG, Lum JJ.

PLoS One. 2013 Dec 23;8(12):e82406. doi: 10.1371/journal.pone.0082406. eCollection 2013.

30.

Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.

Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, Castellarin M, Twumasi-Boateng K, Watson PH, Holt RA, Nelson BH.

Clin Cancer Res. 2014 Mar 1;20(5):1125-34. doi: 10.1158/1078-0432.CCR-13-2147. Epub 2013 Dec 9.

31.

Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.

West NR, Murray JI, Watson PH.

Oncogene. 2014 Mar 20;33(12):1485-94. doi: 10.1038/onc.2013.105. Epub 2013 Apr 15.

PMID:
23584474
32.

Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC).

Yan Y, Li X, Blanchard A, Bramwell VH, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH, Leygue E, Murphy LC.

Ann Oncol. 2013 Aug;24(8):1986-93. doi: 10.1093/annonc/mdt132. Epub 2013 Apr 11.

PMID:
23579816
33.

Biospecimen use correlates with emerging techniques in cancer research: impact on planning future biobanks.

Cole A, Cheah S, Dee S, Hughes S, Watson PH.

Biopreserv Biobank. 2012 Dec;10(6):518-25. doi: 10.1089/bio.2012.0038.

PMID:
24845138
34.

An online tool for improving biospecimen data element reporting.

Cheah S, Dee S, Cole A, Matzke L, O'Donoghue S, Watson PH.

Biopreserv Biobank. 2012 Dec;10(6):501-10. doi: 10.1089/bio.2012.0033.

PMID:
24845136
35.

Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer.

West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, Watson PH.

Br J Cancer. 2013 Jan 15;108(1):155-62. doi: 10.1038/bjc.2012.524. Epub 2012 Nov 20.

36.

Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet).

Matzke EA, O'Donoghue S, Barnes RO, Daudt H, Cheah S, Suggitt A, Bartlett J, Damaraju S, Johnston R, Murphy L, Shepherd L, Mes-Masson AM, Schacter B, Watson PH.

Biopreserv Biobank. 2012 Oct;10(5):426-32. doi: 10.1089/bio.2012.0026.

PMID:
24845043
37.

Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease.

Castellarin M, Milne K, Zeng T, Tse K, Mayo M, Zhao Y, Webb JR, Watson PH, Nelson BH, Holt RA.

J Pathol. 2013 Mar;229(4):515-24. doi: 10.1002/path.4105. Epub 2012 Nov 29.

PMID:
22996961
38.

The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer.

Spowart JE, Townsend KN, Huwait H, Eshragh S, West NR, Ries JN, Kalloger S, Anglesio M, Gorski SM, Watson PH, Gilks CB, Huntsman DG, Lum JJ.

J Pathol. 2012 Dec;228(4):437-47. doi: 10.1002/path.4090.

PMID:
22926683
39.

CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.

Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH.

Clin Cancer Res. 2012 Jun 15;18(12):3281-92. doi: 10.1158/1078-0432.CCR-12-0234. Epub 2012 May 2.

40.

Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer.

West NR, Murphy LC, Watson PH.

Endocr Relat Cancer. 2012 Apr 10;19(2):181-95. doi: 10.1530/ERC-11-0326. Print 2012 Apr.

PMID:
22267707
41.

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH.

Breast Cancer Res. 2011;13(6):R126. doi: 10.1186/bcr3072. Epub 2011 Dec 8.

42.

A proposed schema for classifying human research biobanks.

Watson PH, Barnes RO.

Biopreserv Biobank. 2011 Dec;9(4):327-33. doi: 10.1089/bio.2011.0020. Epub 2011 Oct 3.

PMID:
24836628
43.

The human face of biobank networks for translational research.

Meir K, Gaffney EF, Simeon-Dubach D, Ravid R, Watson PH, Schacter B, Morente And The Marble Arch International Working Group On Biobanking MM.

Biopreserv Biobank. 2011 Sep;9(3):279-85. doi: 10.1089/bio.2011.0018.

PMID:
24850340
44.

What are the main roadblocks to transnational biobank collaboration, and how can we overcome them?

Watson PH, Ravid R, Eng CB, Litton JE, Vaught J, Matusan A.

Biopreserv Biobank. 2011 Sep;9(3):213-6. doi: 10.1089/bio.2011.9340. No abstract available.

PMID:
24850325
45.

Culture medium, gas atmosphere and MAPK inhibition affect regulation of RNA-binding protein targets during mouse preimplantation development.

Calder MD, Watson PH, Watson AJ.

Reproduction. 2011 Nov;142(5):689-98. doi: 10.1530/REP-11-0082. Epub 2011 Aug 16.

PMID:
21846809
46.

Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR).

West NR, Panet-Raymond V, Truong PT, Alexander C, Babinszky S, Milne K, Ross LA, Loken S, Watson PH.

Breast Cancer (Auckl). 2011;5:105-15. doi: 10.4137/BCBCR.S7344. Epub 2011 May 31.

47.

Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence.

Panet-Raymond V, Truong PT, Alexander C, Lesperance M, McDonald RE, Watson PH.

Cancer. 2011 May 15;117(10):2035-43. doi: 10.1002/cncr.25767. Epub 2010 Nov 29.

48.

True recurrence versus new primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy.

Panet-Raymond V, Truong PT, McDonald RE, Alexander C, Ross L, Ryhorchuk A, Watson PH.

Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):409-17. doi: 10.1016/j.ijrobp.2010.05.063. Epub 2011 Feb 1.

PMID:
21288654
49.

Clinical significance of estrogen receptor phosphorylation.

Murphy LC, Seekallu SV, Watson PH.

Endocr Relat Cancer. 2011 Jan 19;18(1):R1-14. doi: 10.1677/ERC-10-0070. Print 2011 Feb. Review.

PMID:
21149515
50.

Ipsilateral breast tumor recurrence after breast-conserving therapy.

Panet-Raymond V, Truong PT, Watson PH.

Expert Rev Anticancer Ther. 2010 Aug;10(8):1229-38. doi: 10.1586/era.10.87. Review.

PMID:
20735309

Supplemental Content

Loading ...
Support Center